UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


WASHINGTON,
  D.C. 20549 

 

FORM 8-K



CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934



Date of report
  (Date of earliest event reported): December 10, 2007

GENTA INCORPORATED


(Exact Name of Registrant as Specified in Its Charter)


Delaware

(State or Other Jurisdiction of Incorporation)


  
     
     
     
  
  
    0-19635

      (Commission File Number) 
     
    33-0326866

      (IRS Employer Identification No.)
  
  
     
     
     
  
  
    200 Connell Drive 

      Berkeley Heights, NJ

    (Address of Principal Executive Offices) 
     
    

      07922

    (Zip Code)
  



(908) 286-9800

  (Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)


 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions:




    o
     
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



     


    o
     
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



     


    o
     
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



     


    o
     
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 
 
 








Item 8.01 Other Events. 
On December 10, 2007, Genta Incorporated, (the Company), announced the release of new survival analyses based upon extended follow-up of patients in the Company’s randomized Phase 3 trial of Genasense® (oblimersen sodium) Injection for relapsed or refractory chronic lymphocytic leukemia (CLL). The new data show that patients who achieved complete remission (the primary endpoint of the trial) with Genasense plus chemotherapy have shown extended survival compared with patients whose complete remission was induced with chemotherapy alone. The data were released this weekend at a press briefing sponsored by the American Society of Hematology (ASH) and will be presented in a scientific session on Tuesday December 11, 2007 at the ASH annual meeting in Atlanta, GA by Dr. Susan O’Brien, Professor of Medicine, M.D. Anderson Cancer Center, Houston, TX.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
 


 
        
      
Exhibit 
 Number
 
        
      
 
 
        
                        
Description
  
 
        
      
99.1
 
        
      
 
 
        
  
Press Release of the Company dated December 10, 2007
  

 
 




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


 
        
                        
 
 
        
                        
 
 
        
                        
GENTA INCORPORATED
  
 
        
                        

 Date: December 10, 2007
 
        
                        
 
 
        
                        
By: 
 
        
                        
 
 /s/ RICHARD J. MORAN
  
 
        
                        
 
 
        
                        
 
 
        
      
 
 
        
      
Name: 
 
        
                        
Richard J. Moran
  
 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
                        
Title: 
 
        
                        
Senior Vice President, Chief Financial Officer and Corporate Secretary
  

 
 




EXHIBIT INDEX
 


 
        
      
Exhibit 
 Number
 
        
      
 
 
        
      
Description
 
        
      
 
 
        
      
Sequentially 
 Numbered Page
  
 
        
      
99.1
 
        
      
 
 
        
      
Press Release of the Company dated December 10, 2007